Related Experiment Video
Updated: Dec 25, 2025
Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
Published on: January 19, 2024
Organoids: A Platform Ready for Glioblastoma Precision Medicine?
Wei-Lin Jin1, Ming-Zhu Jin2, Yan-Yang Tu3
1Center for Translational Medicine, Affiliated Hospital of Guilin Medical University, Guilin 541004, China; Institute of Nano-Biomedicine and Engineering, Department of Instrument Science and Engineering, School of Electronic Information and Electronic Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
Abstract:
Patient-derived organoids can recapitulate parental tumor heterogeneity. In a recent study in Cell, Jacob et al. cultivated glioblastoma organoids (GBOs) to mimic tumor heterogeneity and chimeric antigen receptor (CAR)-T cell immunotherapy, applied it for xenograft establishment and drug testing, and generated a biobank for the timely start of post-operation therapy.
Insights
Patient-derived organoids effectively model glioblastoma heterogeneity. This approach supports chimeric antigen receptor (CAR)-T cell therapy development and personalized treatment strategies.
Area of Science:
- Oncology
- Biotechnology
- Immunotherapy
Background:
- Glioblastoma (GBM) exhibits significant intra-tumor heterogeneity, complicating treatment.
- Patient-derived organoids offer a promising model for studying complex tumors.
- Chimeric antigen receptor (CAR)-T cell therapy shows potential against GBM but requires effective models for development.
Purpose of the Study:
- To develop and characterize glioblastoma organoids (GBOs) that recapitulate parental tumor heterogeneity.
- To utilize GBOs for evaluating chimeric antigen receptor (CAR)-T cell immunotherapy efficacy.
- To establish a biobank of GBOs for rapid drug testing and personalized therapy.
Main Methods:
- Cultivation of patient-derived glioblastoma organoids (GBOs).
- Assessment of GBOs for recapitulating tumor heterogeneity.
- Application of GBOs in xenograft models for immunotherapy and drug testing.
- Generation of a GBO biobank.
Main Results:
- GBOs successfully mimicked the heterogeneity of the parental glioblastoma tumors.
- GBOs served as a viable platform for testing CAR-T cell immunotherapy.
- The established biobank enabled prompt initiation of post-operative therapy studies.
Conclusions:
- Patient-derived glioblastoma organoids are effective models for studying tumor heterogeneity.
- GBOs facilitate the preclinical evaluation of CAR-T cell therapies and drug screening.
- The GBO biobank supports accelerated research and personalized treatment approaches for glioblastoma.
